Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Generic Drugs Market Size to Worth USD 898 Billion by 2035, at a CAGR of 5.75% |…

Generic Drugs Market Enters a High-Momentum, Affordability-First Era Generic Drugs Market Enters a High-Momentum, Affordability-First Era Major trends reshaping the global generics landscape include: The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/generic-drugs-market-1660/request-sample Free Sample Includes: Why CXOs Are Focusing on the Generic Drugs Opportunity Key Market...

Hisense Showcases Smart and Sustainable HVAC Innovations at The Big 5 Global

On display are Rooftop Units, Fresh Air Handling Units (FAHU), Fan Coil Units, Floor Standing Units, Wall Mounted Units in both black and white panels, Touch Controllers, Central and Wired Controllers, and Energy Storage Systems. On display are Rooftop Units, Fresh Air Handling Units (FAHU), Fan Coil Units, Floor Standing Units, Wall Mounted Units in both black and white panels, Touch Controllers, Central and Wired Controllers, and Energy Storage Systems. "At The Big 5 this year, Hisense…

Biocomposites announces expanded approval for STIMULAN® Rapid Cure to be mixed…

KEELE, England, Nov. 25, 2025 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces it has gained an expanded approval in India for STIMULAN® Rapid Cure. The approval from India's Central Drugs Standard Control Organisation (CDSCO) allows STIMULAN® Rapid Cure to be mixed with a wider variety of antibiotics than before, including in…

RefluxStop® 'Best in Class' at Japan Foregut Conference as 5-Year Data and…

Key Data Presentations: Key Data Presentations: "The significant increase in the prevalence of GERD inJapanis driving both interest and the need for a solution like RefluxStop, that addresses the true cause of the disease, an anatomical failure of the body's natural anti-reflux barrier," said Prof. Yano, Jikei University, Tokyo Dr.Peter Forsell, CEO and Founder of Implantica, expressed his gratitude and highlighted the significance of the Japanese market. "We are incredibly...

RAMSAY SANTE : Press release on November 25 2025

PRESS RELEASE Paris, 25 thNovember 2025 Update on Ramsay Health Care Limited's review of its strategic options associated with its majority shareholding in Ramsay Générale de Santé On 27 February 2025, Ramsay Générale de Santé acknowledged the announcement of its Australian reference shareholder Ramsay Health Care Limited regarding the review of its strategic options associated with its majority shareholding in Ramsay Générale de Santé.Today, Ramsay...

Novartis data underscore pioneering scientific innovation in Hematology and…

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trialKisqali NATALEE and MONALEESA data add to evidence of long-term benefits for early...

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted…

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatmentDupixent, which inhibits IL4 and IL13, two key and central...

Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational…

Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025Halle (Saale) / Munich, Germany, November 25 , 2025- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its third quarter financial results for the period ended September...

XRP Healthcare LLC Expands First HIPAA-Grade, Open-Source XRPH Wallet Into U.S…

The wallet is available for free worldwide on Google Play and the App Store. The wallet is available for free worldwide onGoogle Play and the App Store . A Massive Addressable Market Across Two Strategic Healthcare Regions United States Healthcare Market East Africa Healthcare Market ( Kenya,Uganda,Rwanda,Tanzania ) Combined, these regions represent over 400,000 potential healthcare access points and a multi-hundred-billion-dollar transaction landscape...

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study…

According to data released by GLOBOCAN 2022, in 2022, China saw 1.06 million new lung cancer cases (22.0% of all new cancer cases in China) and 0.73 million lung cancer deaths (28.5% of all cancer-related deaths in China). NSCLC was the predominant subtype, accounting for approximately 85% of all lung cancer cases. Among NSCLC patients, non-squamous NSCLC constituted approximately 65% of cases.Immunotherapy (I-O), represented by anti-PD-1 monoclonal antibodies, has become a cornerstone...

Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During…

Short Bowel Syndrome Market Summary Short Bowel Syndrome Market Summary Discover the new short bowel syndrome treatment @Short Bowel Syndrome Treatment Market Key Factors Driving the Growth of the Short Bowel Syndrome Market Rising SBS Prevalence The Short Bowel Syndrome market is largely driven by the increasing prevalence of gastrointestinal conditions that frequently require major bowel resections, resulting in a higher incidence of SBS. Unique GATTEX/REVESTIVE...

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy…

Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studiesOne-time dose of Itvisma replaces SMN1 gene, potentially reducing the need for chronic SMA treatmentGene replacement therapy now available to eligible people of all ages living with SMABasel, November 24, 2025– Novartis today announced that the US Food and Drug...

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along…

Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”)Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regions...

Innocan Pharma Announces Promising Translational Evidence from a Pain Relief…

The results of this study offer clinically translatable information. LPT-CBD injections every 6 weeks are practical, have shown no adverse effects, and provide long-term CBD plasma concentrations. Additionally, LPT-CBD demonstrated remarkable efficacy trends in pain control and wellbeing improvement for several weeks and can potentially provide similar results in people. The results of this study offer clinically translatable information. LPT-CBD injections every 6 weeks are practical, have...

Information relating to the stabilization activities carried out in the context…

Daix (France), New York City (New York, United States), November 24, 202 5 – Publication of information relating to the stabilization activities carried out in the context of the recent public offering of Inventiva (the "Company" or "Inventiva") in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01. As announced on 18 November 2025, the…

U.S. Software as a Medical Device Market to Reach USD 715 Million by 2033 as…

From AI-based triage tools to remote cardiac monitoring and digital diabetes management platforms, SaMD is reshaping the care continuum, improving patient outcomes, and strengthening clinical efficiency across hospitals, ambulatory centers, and home-care settings. From AI-based triage tools to remote cardiac monitoring and digital diabetes management platforms, SaMD is reshaping the care continuum, improving patient outcomes, and strengthening clinical efficiency across hospitals, ambulatory...

CARBIOS signs two new multi-year commercial agreements for recycled PET with…

Clermont-Ferrand (France), 24 November 2025 (18h30 CET). CARBIOS(Euronext Growth Paris : ALCRB), announces the signing of two new multi-year commercial agreements with major players in beverage industry, for the supply of recycled PET (r-PET). The signing of these two new commercial agreements marks CARBIOS’s entry into a new strategic sector: beverages.These new commercial agreements are part of the pre-commercialization process for CARBIOS’s future industrial site, bringing the...

Press release: Transparency Notification from Shareholders

Transparency Notification from ShareholdersGhent, Belgium – 24 November 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table…

Aesthetic Fillers Market Surges to USD 8.45 Billion by 2033, Propelled by 7.2%…

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=837080&utm_source=PRNewswire&utm_medium=360 Download PDF Brochure:https://www.verifiedmarketreports.com/download-sample/?rid=837080&utm_source=PRNewswire&utm_medium=360 Browse in-depth TOCon Aesthetic Fillers Market 202 - Pages 126 – Tables 37 – Figures Scope of The Aesthetic Fillers Market Report Global Aesthetic Fillers Market Overview Hybrid fillers that blend...

Scott LaNeve Named President of Labstat International

LaNeve brings more than 30 years of leadership experience across life sciences, laboratory diagnostics, and healthcare technology. His career includes senior roles at industry leaders such as Abbott Laboratories, Roche Diagnostics, and Quest Diagnostics, as well as executive positions within national laboratory networks and technology organizations, where he led operational transformation and strengthened client engagement. LaNeve brings more than 30 years of leadership experience across life...

Pet Biotics Market worth $1,232.5 million by 2030- Exclusive Report by…

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and…

Catalyx Report Reveals Persistent Manufacturing Bottlenecks in Life Sciences…

Zelluna ASA – Extraordinary General Meeting held on November 25, 2025

Generic Drugs Market Size to Worth USD 898 Billion by 2035, at a CAGR of 5.75% |…

Hisense Showcases Smart and Sustainable HVAC Innovations at The Big 5 Global

Biocomposites announces expanded approval for STIMULAN® Rapid Cure to be mixed…

RefluxStop® 'Best in Class' at Japan Foregut Conference as 5-Year Data and…

RAMSAY SANTE : Press release on November 25 2025

Novartis data underscore pioneering scientific innovation in Hematology and…

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted…

Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational…

XRP Healthcare LLC Expands First HIPAA-Grade, Open-Source XRPH Wallet Into U.S…

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study…

Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During…

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy…

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along…

Innocan Pharma Announces Promising Translational Evidence from a Pain Relief…

Information relating to the stabilization activities carried out in the context…

U.S. Software as a Medical Device Market to Reach USD 715 Million by 2033 as…

CARBIOS signs two new multi-year commercial agreements for recycled PET with…

Press release: Transparency Notification from Shareholders

Aesthetic Fillers Market Surges to USD 8.45 Billion by 2033, Propelled by 7.2%…

Scott LaNeve Named President of Labstat International